Carlsmed Appoints Richard Heppenstall as Chief Financial Officer
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Carlsmed (CARL) appointed Richard Heppenstall chief financial officer, succeeding Leo Greenstein, and reaffirmed its fiscal 2026 revenue outlook. Heppenstall takes the role immediately. Greenstein, CFO since 2023, is leaving to pursue other professional interests. Full-year revenue guidance remains $74 million to $78 million, representing 50% growth over 2025 at the range’s midpoint.
CMS reimbursement for the aprevo Lumbar spinal fusion procedure is set to take effect October 1. Carlsmed also expects to launch the aprevo Lumbar Bi-lateral and corra cervical procedures.
Positive
$74 million to $78 million in full-year 2026 revenue guidance reaffirmed, representing 50% growth over 2025 at the midpoint.
CMS reimbursement for the aprevo Lumbar spinal fusion procedure takes effect October 1.
aprevo Lumbar Bi-lateral procedure launch is upcoming.
corra cervical procedure launch is upcoming.
Negative
- None.
Details
Market move: CARL -6.09% in the Sep 28 session. CFO appointment
On Sep 28, the day this news came out, CARL closed 6.09% below the previous close. Argus tracked a trough of -2.7% from its starting point during tracking. Our momentum scanner recorded 15 alerts for this stock that day.
Data tracked by StockTitan Argus for the Sep 28 session.
Key Figures
- FY2026 revenue guidance
- $74 to $78 million
- Reaffirmed full-year outlook
- Revenue growth at midpoint
- 50%
- Growth over 2025 at the midpoint of FY2026 guidance
- CMS reimbursement effective date
- October 1, 2026
- For the aprevo Lumbar spinal fusion procedure
Historical Context
-
Raised full-year revenue guidance after Q2 results, matching the outlook reaffirmed in this release.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
spinal fusion medical
ipo financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company Reaffirms Fiscal Year 2026 Guidance
CARLSBAD, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Richard Heppenstall has been appointed Chief Financial Officer, effective immediately. Mr. Heppenstall succeeds Leo Greenstein, who has served as CFO since 2023 and will be leaving Carlsmed to pursue other professional interests.
“We are excited to welcome Rich to Carlsmed at a pivotal point for the Company,” said Mike Cordonnier, Chairman and CEO. “He is a proven leader with the deep Orthopedic and Tech expertise crucial to driving our strategy, and his deep financial and operational experience will be invaluable as we build upon our momentum, scale the organization, and execute against the substantial opportunity in front of us. With the new aprevo® Lumbar spinal fusion procedure CMS reimbursement going into effect on October 1, and the upcoming launches of the aprevo® Lumbar Bi-lateral procedure and corra™ cervical procedure, we believe we are well positioned for this next phase of execution.”
Mr. Heppenstall is an accomplished financial, strategic, and operational leader bringing nearly 30 years of experience across healthcare, life sciences, and technology. He previously served as the Executive Vice President, Chief Financial Officer and Treasurer of ZimVie Inc. from September 2021 until its acquisition by ArchiMed SAS in October 2025. Prior to ZimVie, Inc., Mr. Heppenstall served as CFO of Breg, Inc. from April 2019 to September 2021. Prior to joining Breg, Inc., he served as Senior Vice President, Finance and Treasury of Orthofix Medical Inc. from May 2015 to April 2019 and previously in senior finance and business leadership positions with Solera Holdings, Flowserve Corporation, and CooperVision. Mr. Heppenstall holds an MBA from Santa Clara University Leavey School of Business and a Bachelor of Arts in Economics from University of California Irvine.
"I look forward to partnering with Mike, our executive team, and the finance organization to build on Carlsmed's strong foundation and support disciplined execution," said Mr. Heppenstall. "With compelling clinical outcomes data, strengthening reimbursement, and a proprietary, patient-centric innovation platform, I'm excited to help advance our vision of making personalized surgery at scale the standard of care for spine surgery."
"On behalf of the Board and the entire Carlsmed team, I want to express my sincere gratitude to Leo for his leadership as CFO for the prior three years," said Mr. Cordonnier. "His disciplined financial management, stewardship through our IPO process, and dedication to strengthening our finance function have positioned Carlsmed for continued success. We wish him all the best."
Reaffirming Full Year 2026 Financial Outlook
The Company is reaffirming its full-year revenue guidance of
About Carlsmed
Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond.
Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects, including statements about Carlsmed’s ability to execute on its strategic priorities and increase adoption of its product offerings, Carlsmed’s ability to scale, Carlsmed’s growth prospects, the impact of CMS’s reimbursement policy on Carlsmed’s business, the timing of Carlsmed’s expected product launches, the revenue ranges presented in our fiscal year 2026 guidance provided on August 5, 2026 and reaffirmed herein and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including such important factors as are set forth under the caption “Risk Factors” in Carlsmed’s Annual Report on Form 10-K on file with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent Carlsmed’s views as of the date of this press release. Carlsmed anticipates that subsequent events and developments will cause its views to change. However, while Carlsmed may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Carlsmed’s views as of any date subsequent to the date of this press release.
Investor Relations
Stephanie Zhadkevich
Vice President, Head of Investor Relations
IR@Carlsmed.com
Media
LeAnn Burton
Senior Director, Brand Marketing
Marketing@Carlsmed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who is Carlsmed's new CFO?
Richard Heppenstall has been appointed Carlsmed’s CFO, effective immediately. He succeeds Leo Greenstein, who is leaving to pursue other professional interests.
What is Carlsmed's fiscal 2026 revenue guidance?
Carlsmed reaffirmed full-year 2026 revenue guidance of $74 million to $78 million. The company said the range represents 50% growth over 2025 at its midpoint.